The accompanying notes are an integral part of
these consolidated financial statements.
The accompanying notes are an integral part of
these consolidated financial statements.
The accompanying notes are an integral part of
these consolidated financial statements.
The accompanying notes are an integral part of
these consolidated financial statements.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
1. NATURE OF THE BUSINESS
Cryomass Technologies Inc (“Cryomass Technologies”
or the “Company”) began as Auto Tool Technologies Inc., which was incorporated under the laws of the State of Nevada on May
10, 2011. The Company’s name was changed to AFC Building Technologies Inc. effective January 10, 2014. Effective April 26, 2018,
the Company changed its name to First Colombia Development Corp. Effective October 14, 2019, the Company changed its name to Redwood Green
Corp. Effective September 1, 2020, the Company changed its name to Andina Gold Corp. On July 15, 2021, the Company entered into a plan
of merger with its wholly-owned subsidiary, Cryomass Technologies Inc a Nevada corporation, pursuant to which we agreed that subsidiary
would merge with and into our company. Following the consummation of the merger, the separate existence of the subsidiary ceased, and
we continued as the surviving corporation with our name changed to Cryomass Technologies Inc. effective August 27, 2021. Our ticker symbol
changed from AGOL to CRYM.
The Company’s principal office is located
at 1001 Bannock St., Suite 612, Denver, CO 80204, and its telephone number is 303-416-7208. The Company’s website is www.cryomass.com.
Information appearing on the website is not incorporated by reference into this prospectus.
The Company over its history has explored a number
of different business opportunities.
On May 10, 2018, the Company acquired all the
issued and outstanding share capital of First Colombia Devco S.A.S. (“Devco”) a Colombian company and began to establish various
business ventures in Colombia in the agriculture and real estate development, tourism, and infrastructure sectors before commencing to
phase them out in April 2019.
On July 1, 2019, the Company acquired 100% of
the membership interests in General Extract, LLC (“General Extract”), a Colorado limited liability company. General Extract
was founded in 2015 as an importer, distributor, broker and postprocessor of hemp and hemp derivatives. The Company acquired all of the
issued and outstanding membership interests, including business plans and access to contacts. Effective August 27, 2021, General Extract
became Cryomass LLC.
On July 15, 2019, the Company, through its wholly
owned subsidiary Good Acquisition Co., entered into a Membership Interest Purchase Agreement to acquire cannabis-related intellectual
property and other assets of Critical Mass Industries LLC DBA Good Meds (“CMI” and/or “Good Meds”), a Colorado
limited liability company (“CMI Transaction”). CMI is licensed by the Marijuana Enforcement Division of Colorado Department
of Revenue to produce cannabis and cannabis products under its six licenses. These licenses allow for cultivation, manufacturing of infused
products and retail distribution. At the time the Company entered into the Membership Interest Purchase Agreement, Colorado law prohibited
public companies, including the Company, from owning cannabis licenses. Therefore, CMI spun off certain assets acquired by the Company.
Under the terms of the Membership Interest Purchase Agreement, CMI retained the cannabis license, inventory and accounts receivable (the
“Cannabis License Assets”) and continued to operate the cannabis business related to those assets. In consideration for the
transfer of the acquired assets, the Company delivered 13,553,233 shares of the Company common stock, in addition to $1,999,770 in cash
to CMI.
Good Meds, the operating unit of CMI, is based
in Denver, CO, and operates in a 60,000-square-foot cultivation and processing facility. This facility produces cannabis for sale as dry
flower and biomass input for processing into Marijuana-Infused Products (“MIP”), such as live resin, wax and budder. Good
Meds also owns and operates two medical cannabis dispensaries located in Lakewood, CO and Englewood, CO. The business has been in operation
since 2009.
CRYOMASS TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
Effective December 31, 2021, we entered into a
restated and amended administrative services agreement, terminated our license and marketing agreements, and restated the asset purchase
agreement with CMI and affiliates. As a result of these agreements, we disposed of all CMI-related assets and extinguished any and all
related obligations. For clarity, we have no management or operations decision-making right or responsibility, nor any access to future
economic benefits from operation of the assets. Therefore, upon commencing these agreements, we determined that CMI no longer qualifies
as a variable interest entity as of December 31, 2021.
Beginning in March 2020, an evaluation of various
strategic alternatives was followed by the decision to sell the Colorado-based assets and refocus its attention on unique opportunities
for gold exploration in Colombia. In August 2020, the Company established a wholly owned Colombian subsidiary, Andina Gold Colombia SAS
for this purpose. In December 2020, due to the death of the top geologist exploring opportunities on behalf of the Company, and the effects
of the ongoing Coronavirus pandemic, the Company determined that pursuit of gold exploration in Colombia was no longer a practical alternative.
On June 22, 2021, the Company entered into an
Asset Purchase Agreement with Cryocann USA Corp, a California corporation (“Cryocann”), pursuant to which Company acquired
substantially all the assets of Cryocann. The aggregate purchase price was $3,500,000 million in cash and 10,000,000 shares of Company
common stock As part of the Cryocann Acquisition, we retained both Cryocann employees, who have expert knowledge of the industry, related
participants, customers and the acquired patented technology. Under their employment agreements, each employee may receive compensation
if specific performance targets are met in association with our future operating performance when the Cryocann technology enters the market.
The technology and assets acquired from Cryocann are operated from the Company’s subsidiary, Cryomass LLC. The patented cryo-mechanical
technology is for the separation of plant materials in the harvesting of hemp and cannabis, and potentially other high value crops such
as hops. We believe this technology will reduce processing costs and increases the quality of extracted compounds. We are exploring the
application of the underlying technology to a broad range of industries that handle high-value materials and that could benefit from our
precision capture methods. We anticipate that cannabis and hemp will be the first in a series of such industries.
To develop and commercialize the technology,
we contracted with an independent engineering and manufacturing firm to refine the design of our cryo-mechanical system for the
handling of harvested hemp, cannabis and other high-value plants. The system exploits CryoMass’s U.S.-patented process
for the controlled application of liquid nitrogen to stabilize and separate the structural elements of gross plant material. The
device currently under development is scaled for highway transportability and is being optimized for the low-cost collection of
fully intact hemp and cannabis trichomes. It can be used within minutes after plants have been cut and can also efficiently capture
trichomes from fresh frozen or even dried plant parts, including trim. The device’s through-put capacity is expected to be
approximately 600 kilograms of gross plant material per hour. The advanced design for the equipment has been completed,
and testing of a prototype machine is currently underway. The engineering and manufacturing firm has indicated that it has the
capacity to build 10 to 15 such devices per month.
In November we retained a second engineering
and manufacturing firm to independently develop a separate machine design that applies our patented process. We expect their work to help
strengthen the power and robustness of our technology. In addition, it opens a channel to a second manufacturing source.
The first functional “beta” machine
is expected to be ready for field testing by a third-party cannabis producer by mid-2022. The first production-run machine is expected
to be ready for use towards the end of the second quarter 2022. At that moment, we expect to start helping our first tolling client (fee
for service) increase its margins by cutting the cost of handling, processing and refining its hemp or cannabis and increasing
the resulting material’s value to formulators of end products.
CRYOMASS TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
Management believes the CryoMass system
will deliver a compelling combination of cost and time savings while enhancing product quality and quantity for largescale cultivators
and processors of hemp and cannabis. The use of a CryoMass system – which can be trucked to and operated on the fields
of most large hemp and cannabis growers or be permanently installed at a user’s processing facility – should eliminate many
of the costs that come with traditional practices, especially the labor, fuel and capital costs of drying and curing hemp or
cannabis that is grown for the extraction of end products. With traditional practices, harvested plants are transported to a specially
constructed drying house and then treated for a week or longer under controlled conditions of temperature and humidity. It’s a costly
method. With our system, harvested plants are simply fed into the front end of a CryoMass machine, and minutes later fully intact
trichomes are collected at the back end of the machine. With traditional practices and their seven-to-ten days of handling and drying,
a large share of a plant’s valuable trichomes break off and are lost. Then the remaining trichomes are damaged by long exposure
to oxygen and by the evaporation of their volatile terpenes. The CryoMass system, on the other hand, stabilizes and collects
fully intact trichomes at harvest, leaving no opportunity for such wasteful loss. Field-captured trichomes are the cleanest element of
a hemp or cannabis plant because, unlike the rest of the plant, trichomes do not readily take up heavy metals, pesticides or
other common soil contaminants. As a product for end-users, field-captured trichomes are closest to being contaminant free. As feedstock
for manufacturers of extracts and oils, they are the key to the purest products possible.
Because the trichomes collected with CryoMass technology
represent only 10% or so of a plant’s weight and volume, they are cheaper to ship and store than gross plant material. For
the same reason and because trichomes are free of the waxes and other unwanted materials found in the rest of the plant, processing trichomes
into oils and extracts can be far quicker, cheaper and easier than processing gross plant material. Even trichomes captured
from dried or frozen plant parts deliver this cost-saving advantage to processors of oils and extracts. The three-dimensional advantage
achievable with the CryoMass system – first-stage cost savings, product enhancement and downstream cost savings –
can as much as double a crop’s wholesale value. And in some jurisdictions, users may enjoy a reduction in excise taxes levied on
cannabis and hemp harvests, which typically are tied to the gross weight of hemp or cannabis that is removed from the field.
Production and processing of hemp and cannabis
is a huge, worldwide industry. In the U.S., for example, the wholesale value of the cannabis crop from just the 11 states permitting adult-use
and medical cannabis exceeds $6 billion annually.1 Growth in the U.S. and in the worldwide market is likely fed
in part by the growing acceptance of medicinal cannabis products and anticipated legislative changes in various jurisdictions worldwide.
And that may only be chapter one of the Company’s
story. Several other high-value plants, including species that are important for health and wellness products, wrap their valuable elements
in trichomes. The technology we are developing for hemp and cannabis may have profitable application to those other species as well. We
intend to find out.
In September, we were granted an additional
patent for our process from the Chinese Intellectual Property Office. We currently are taking steps to gain further protection for our
intellectual property through the European Union Intellectual Property Office and several other international jurisdictions.
On November 17th we announced
the completion of a $10.3 million equity financing. The financing and the earlier conversion of substantially all the company’s
debt into common stock left the Company with a strong balance sheet and adequate resources for our planned business development during
the coming twelve months. In connection with the financing, 1,010,000 shares and 760,000 shares of CryoMass Technologies
common stock were purchased by CEO Christian Noël and Chairman of the Board Delon Human, respectively.
CRYOMASS TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
2. VARIABLE INTEREST ENTITY
Pursuant to Financial Accounting Standards Board
(“FASB”) Accounting Standards Codification (“ASC”) Section 810, Consolidation (“ASC 810”),
the Company is required to include in its consolidated financial statements, the financial statements of its variable interest entity
(“VIE”). ASC 810 requires a VIE to be consolidated if that company is subject to a majority of the risk of loss for the VIE
or is entitled to receive a majority of the VIE’s residual returns. VIEs are those entities in which a company, through contractual
arrangements, bears the risk of, and enjoys the rewards normally associated with ownership of the entity, and therefore the company is
the primary beneficiary of the entity.
Under ASC 810, a reporting entity has a controlling
financial interest in a VIE, and must consolidate that VIE, if the total equity investment at risk is not sufficient to permit the legal
entity to finance its activities without additional subordinated financial support provided by any parties, including equity holders.
Beginning July 15, 2019, the Company consolidated CMI as a VIE pursuant to certain intellectual property, administrative and consulting
agreements in which the Company is deemed the primary beneficiary of CMI. Accordingly, the results of CMI have been included in the accompanying
consolidated financial statements. Effective December 31, 2021, the Company entered into an asset purchase agreement involving its VIE
with Critical Mass Industries, Inc. and John Knapp, the sole shareholder of Critical Mass Industries, Inc., to divest its discontinued
operations in cannabis cultivation, where the buyer assumes all assets and liabilities from the Company. Therefore, with regards to both
criteria discussed above, the Company no longer has the power to direct activities, absorb losses, or receive benefits from the VIE and
as such will no longer consolidate with CMI.
CMI Assets & Liabilities |
| |
As of December 31, | |
Description | |
2021 | | |
2020 | |
Current assets | |
| | |
| |
Cash and cash equivalents | |
$ | - | | |
$ | 196,445 | |
Accounts receivable, net | |
| - | | |
| 66,043 | |
Inventory, net | |
| - | | |
| 791,868 | |
Total current assets | |
| - | | |
| 1,054,356 | |
| |
| | | |
| | |
Total assets | |
$ | - | | |
$ | 1,054,356 | |
| |
| | | |
| | |
Current liabilities | |
| | | |
| | |
Accounts payable and accrued expenses | |
$ | - | | |
$ | 211,463 | |
Total current liabilities | |
| - | | |
| 211,463 | |
| |
| | | |
| | |
Total liabilities | |
| - | | |
| 211,463 | |
Net assets | |
$ | - | | |
$ | 842,893 | |
CRYOMASS TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
CMI Statement of Operations |
| |
For the Years Ended December 31, | |
Description | |
2021 | | |
2020 | |
Net sales | |
$ | 5,891,894 | | |
$ | 6,860,282 | |
Cost of goods sold, inclusive of depreciation | |
| 4,132,696 | | |
| 4,901,237 | |
Gross profit | |
$ | 1,759,198 | | |
$ | 1,959,045 | |
| |
| | | |
| | |
Operating expenses | |
| | | |
| | |
Personnel costs | |
| 428,728 | | |
| 402,389 | |
Sales and marketing | |
| 816,683 | | |
| 908,502 | |
General and administrative | |
| 112,934 | | |
| 231,376 | |
Legal and professional fees | |
| 44,092 | | |
| 156,782 | |
Amortization expense | |
| - | | |
| 26,901 | |
Total operating expenses | |
| 1,402,437 | | |
| 1,725,950 | |
Gain from operations | |
$ | 356,761 | | |
$ | 233,095 | |
| |
| | | |
| | |
Other income / (expense) | |
| | | |
| | |
Interest expense | |
| (49,803 | ) | |
| (153,592 | ) |
Goodwill impairment | |
| - | | |
| (4,663,514 | ) |
Intangibles impairment | |
| - | | |
| (361,218 | |
Other income | |
| - | | |
| - | |
Total other income / (expense) | |
| (49,803 | ) | |
| (5,178,324 | ) |
Loss on disposal of discontinued operations | |
| (3,021,724 | ) | |
| - | |
Net income / (loss), before taxes | |
| (2,714,766 | ) | |
| (4,945,229 | ) |
Income taxes | |
| (10,235 | ) | |
| (10,235 | ) |
Net income / (loss), net of taxes | |
$ | (2,725,001 | ) | |
$ | (4,955,464 | ) |
As a result of new agreements entered with CMI
on December 31, 2021, as further detailed in Note 1 above, we disposed of all CMI-related assets and extinguished any and all related
obligations in exchange for a $3,600,000 promissory note due to us no later than December 31, 2023. When comparing the carrying value
of CMI-related net assets to the value of the loan receivable, we calculated a loss on disposal of discontinued operations of $3,021,724.
3. GOING CONCERN UNCERTAINTY, FINANCIAL CONDITIONS
AND MANAGEMENT’S PLANS
The Company believes it has sufficient cash available
to fund its anticipated level of operations for at least the next twelve months. During the year, the Company raised $10,548,535 in common
stock and $4,900,000 in convertible notes which were all converted to common stock.
While management believes the Company has sufficient
cash available to support an anticipated level of operations for at least the next twelve months, the continuation of our company as a
going concern is dependent upon the continued financial support from its shareholders, the ability of our company to obtain necessary
equity or debt financing to continue operations, the sale of assets, and ultimately the attainment of profitable operations. For the year
ended December 31, 2021, our company used $5,600,512 of cash for operating activities, incurred a net loss of $12,859,643 and has an accumulated
deficit of $28,588,837 since inception.
On March 11, 2020, the 2019 novel coronavirus
(“COVID-19) was characterized as a “pandemic.” The Company’s operations were impacted during the year
in the United States. The impact of COVID-19 developments and uncertainty with respect to the economic effects of the pandemic has
introduced significant volatility in the financial markets.
The Company assessed certain accounting matters
that require consideration of forecasted financial information, including, but not limited to, the carrying value of the Company’s
goodwill, intangible assets, and other long-lived assets, and valuation allowances in context with the information reasonably available
to the Company and the unknown future impacts of COVID-19 as of December 31, 2021 and through the date of this report. The Company’s
future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Consolidated
Financial Statements in future reporting periods.
CRYOMASS TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
The COVID-19 pandemic and responses to this crisis,
including actions taken by federal, state and local governments, have had an impact on the operations of the company, including, without
limitation, the following: reduced staffing due to employee suspected conditions and social distancing measures; constraints on productivity;
management and staff non-essential business-related travel was constrained due to stay-at-home orders; most employees have shifted to
remote work resulting in loss of productivity; consumers visiting dispensaries operated under license impacted by stay-at-home orders.
Management continues to monitor the COVID-19 pandemic situation and federal, state and local recommendations and will provide updates
as appropriate.
4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Principles of Consolidation
The accompanying consolidated financial statements
have been prepared in accordance with GAAP. The consolidated financial statements include the accounts of the Cryomass Technologies Inc,
Cryomass LLC, and CMI, a VIE for which the Company was deemed to be the primary beneficiary. All significant intercompany balances and
transactions have been eliminated in consolidation. The Company operates as one segment from its corporate headquarters in Colorado.
Effective December 31, 2021, the Company entered
into an asset purchase agreement involving its VIE with Critical Mass Industries, Inc. and John Knapp, the sole shareholder of Critical
Mass Industries, Inc., to divest its discontinued operations in cannabis cultivation, where the buyer assumes all assets and liabilities
from the Company. Therefore, with regards to both criteria discussed above, the Company no longer has the power to direct activities,
absorb losses, or receive benefits from the VIE and as such will no longer consolidate with CMI.
Use of Estimates
The preparation of the Company’s financial
statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of
expenses during the reporting period. Significant estimates and assumptions reflected in these financial statements include, but are not
limited to determining the fair value of the assets acquired and liabilities assumed in acquisition, determining the fair value and potential
impairment of inventory, determining the useful lives and potential impairment of long-lived assets and potential impairment of goodwill.
The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes
to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances,
facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those
estimates.
Reclassifications
Certain items in the consolidated financial statements
were reclassified from prior periods for presentation purposes.
Cash and Cash Equivalents
The Company considers all highly liquid instruments
with maturities of three months or less at the time of issuance to be cash equivalents.
CRYOMASS TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
Concentrations of Credit Risk
Financial instruments that potentially subject
the Company to concentrations of credit risk consist principally of cash. Periodically, the Company maintains deposits in accredited financial
institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high
credit quality and has not experienced any losses on such accounts. Additionally, the company entered into a $3,600,000 loan receivable
in conjunction with the disposal of discontinued operations, which is backed by the assets of the discontinued operations, should the
borrower default. Aside from these items, the Company does not believe it is exposed to any unusual credit risk.
Purchase Accounting for Acquisitions
We apply the acquisition method of accounting
for a business combination. In general, this methodology requires us to record assets acquired and liabilities assumed at their respective
fair values at the date of acquisition. Any amount of the purchase price paid that is in excess of the estimated fair value of the net
assets acquired is recorded as goodwill. For certain acquisitions, we also record a liability for contingent consideration based on estimated
future business performance. We monitor our assumptions surrounding these estimated future cash flows and, if there is a significant change,
would record an adjustment to the contingent consideration liability and a corresponding adjustment to either income or expense. We determine
fair value using widely accepted valuation techniques, primarily discounted cash flow and market multiple analyses. These types of analyses
require us to make assumptions and estimates regarding industry and economic factors, the profitability of future business strategies,
discount rates and cash flow.
If actual results are not consistent with our
assumptions and estimates, or our assumptions and estimates change due to new information, we may be exposed to an impairment charge in
the future. If the contingent consideration paid for any of our acquisitions differs from the amount initially recorded, we would record
either income or expense associated with the change in liability.
Variable Interest Entities
The Company accounts for variable interest entities
in accordance with FASB ASC Topic 810, Consolidation. Management evaluates the relationship between the Company and VIEs and
the economic benefit flow of the contractual arrangement with the VIEs. Management determines if the Company is the primary beneficiary
of a VIE through a qualitative analysis that identifies which variable interest holder has the controlling financial interest in the VIE.
The variable interest holder who has both of the following has the controlling financial interest and is the primary beneficiary: (1)
the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (2) the obligation
to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. In performing our
analysis, we consider all relevant facts and circumstances, including: the design and activities of the VIE, the terms of the contracts
the VIE has entered into, the nature of the VIE’s variable interests issued and how they were negotiated with or marketed to potential
investors, and which parties participated significantly in the design or redesign of the entity. As a result of such evaluation, management
concluded that the Company is the primary beneficiary of CMI and consolidates the financial results of this entity. Effective December
31, 2021, the Company entered into an asset purchase agreement involving its VIE with Critical Mass Industries, Inc. and John Knapp, the
sole shareholder of Critical Mass Industries, Inc., to divest its discontinued operations in cannabis cultivation, where the buyer assumes
all assets and liabilities from the Company. Therefore, with regards to both criteria discussed above, the Company no longer has the power
to direct activities, absorb losses, or receive benefits from the VIE and as such will no longer consolidate with CMI.
Accounts Receivable, net
Accounts receivable, net is comprised of balances
due from customers and are recorded at the invoiced amount. Past due balances are determined based on the contractual terms of the arrangements.
Accounts receivable are accrued against when management determines, after considering economic and business conditions and all means of
collection efforts have been exhausted and the potential for recovery is considered remote, that the collection of receivables is doubtful.
Accounts receivable amounts, net of allowance for doubtful accounts, were $0 and $606,043 as of December 31, 2021 and 2020, respectively.
This includes $0 and $66,043, respectively, related to the VIE. Uncollectible accounts previously recorded as receivables are recognized
as bad debt expense, with a corresponding decrease to accounts receivable. Bad debt expense was $541,099 and $188,548 for the years ended
December 31, 2021 and 2020, respectively. This amount includes $1,099 and $4,548, respectively, related to the VIE, which is classified
as discontinued operations.
CRYOMASS TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
Inventory, net
Inventory, net is comprised of work-in-process
and finished goods consisting of cannabis and cannabidiol products. Cost includes expenditures directly related to the manufacturing process
as well as suitable portions of related production overheads, based on normal operating capacity. Inventory, net is stated at the lower
of cost or net realizable value. The Company compares the cost of inventory with market value and writes down inventories to net realizable
value, if lower. In evaluating whether inventories are stated at lower of cost or net realizable value, management considers such factors
as inventories on hand, physical deterioration, obsolescence, changes in price levels, estimated time to sell such inventories and current
market conditions. Due to changing market conditions, management conducted a thorough review of its inventory. As a result, a provision
for inventory losses of $0 and $400,787 was charged against cost of goods sold during the years ended December 31, 2021 and 2020, respectively,
due to a write down of inventory to its net realizable value. This was based on the Company’s best estimates of product sales prices
and customer demand patterns. It is at least reasonably possible that the estimates used by the Company to determine its provision for
inventory losses will be materially different from the actual amounts or results. These differences could result in materially higher
than expected inventory provisions, which could have a materially adverse effect on the Company’s results of operations and financial
conditions in the near term.
Revenue Recognition
Under FASB Topic 606, Revenue from Contacts
with Customers (“ASC 606”), the Company recognizes revenue when the customer obtains control of promised goods or services,
in an amount that reflects the consideration which is expected to be received in exchange for those goods or services. The Company recognizes
revenue following the five-step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance
obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s)
in the contract; and (v) recognize revenues when (or as) the Company satisfies a performance obligation.
Discontinued Operations
The Company’s revenue consists of sales
of cannabis and ancillary products to both retail consumers and wholesale customers. Revenue for retail customers is recognized upon completion
of the transaction in the point of sale system and satisfaction of the sale by providing the corresponding inventory at the retail location.
Revenue for wholesale customers is recognized upon acceptance of the physical goods and confirmation by acceptance of the inventory in
the regulatory marijuana enforcement tracking reporting compliance (“METRC”) system. Revenue is recognized upon transfer of
control of promised products to customers, generally as risk of loss passes, in an amount that reflects the consideration the Company
expects to receive in exchange for those products. Taxes collected from customers, which are subsequently remitted to governmental authorities,
are excluded from revenue.
Retail customer loyalty liabilities are recognized
in the period in which they are incurred and will often be retired without being utilized. Shipping and handling costs are expensed as
incurred and are included in cost of sales, which were not material for the years ended December 31, 2021 and 2020.
The Company operates in a highly regulated environment
in which state regulatory approval is required prior to the customer being able to purchase the product, either through the Colorado Marijuana
Enforcement Division for wholesale clients or the Colorado Department of Public Health and Environment for medical patients.
Expenses
Operating Expenses
Operating expenses encompass personnel costs,
sales and marketing expenses, general and administrative expenses, professional and legal fees and depreciation and amortization related
to the property and equipment and intangibles acquired through the acquisition of CMI and Cryocann. Personnel costs consist primarily
of consulting expense and administrative salaries and wages. Sales and marketing expenses consist primarily of advertising and marketing,
and salaries related to sales and marketing employees. General and administrative expenses are comprised of travel expenses, accounting
expenses, and board fees. Professional services are principally comprised of outside legal and professional fees.
Discontinued Operations
Cost of Goods Sold, Net of Depreciation
and Amortization
Cost of goods sold primarily consisted of allocated
salaries and wages of employees directly related with the production process, allocated depreciation and amortization directly related
to the production process, cultivation supplies, rent and utilities.
CRYOMASS TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
Other Expense, net
Other expense, net consisted of interest expense,
other income and (loss) gain on foreign exchange.
Stock-Based Compensation
The fair value of restricted stock units (“RSUs”)
granted are measured on the grant date using the closing price of the Company’s common shares on the grant date. For stock
options, the Company engages a valuation firm to calculate the grant date fair value of the options issued. The Company accounts for forfeitures
as they occur, rather than estimating expected forfeitures over the course of a vesting period. All stock-based compensation costs are
recorded in general and administrative expenses in the consolidated statements of operations.
Property and Equipment, net
Purchase of property and equipment are recorded
at cost. Improvements and replacements of property and equipment are capitalized. Maintenance and repairs that do not improve or extend
the lives of property and equipment are charged to expense as incurred. When assets are sold or retired, their cost and related accumulated
depreciation are removed from the accounts and any gain or loss is reported in the consolidated statements of operations. Depreciation
and amortization expense is recognized using the straight-line method over the estimated useful life of each asset, as follows:
| |
Estimated Useful Life |
Computer equipment | |
3 – 5 years |
Furniture and fixtures | |
5 – 7 years |
Machinery and equipment | |
5 – 8 years |
Leasehold improvements | |
Shorter of lease term or 15 years |
Goodwill and Intangible Assets
Goodwill represents the excess of the purchase
price of an acquired entity over the fair value of identifiable tangible and intangible assets acquired and liabilities assumed in a business
combination.
Indefinite-lived intangible assets established
in connection with business combinations consists of in process research and development. Intangible assets with indefinite lives are
recorded at their estimated fair value at the date of acquisition. Once in process research and development is placed in service, it will
be amortized over the estimated useful life.
Intangible assets with finite lives are recorded
at their estimated fair value at the date of acquisition and are amortized over their estimated useful lives using the straight-line method.
Amortization of assets ceases upon designation as held for sale. The estimated useful lives of intangible assets are detailed in the table
below:
| |
Estimated Useful Life |
Patent | |
10 years |
In process research and development | |
Indefinite |
CRYOMASS TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
Impairment of Goodwill and Intangible Assets
Goodwill
Goodwill is not amortized, but instead is tested
annually at December 31 for impairment and upon the occurrence of certain events or substantive changes in circumstances.
We account for the impairment of goodwill under
the provisions of Financial Accounting Standards Board (FASB) Accounting Standard Update 2017-04 (“ASU 2017-04”), “Intangibles
– Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” and FASB Accounting Standards Codification
(ASC) 350-20-35, Intangibles – Goodwill and Other – Goodwill.
The Company performs impairment testing for goodwill
by performing the following steps: 1) evaluate the relevant events or circumstances to determine whether it is more likely than not that
the fair value of a reporting unit is less than its carrying amount, 2) if yes to step 1, calculate the fair value of the reporting unit
and compare it with its carrying amount, including goodwill, 3) recognize impairment, limited to the total amount of goodwill allocated
to that reporting unit, equal to the excess of the carrying value of a reporting unit over its fair value.
During the year ended December 31, 2020, the Company
concluded that goodwill resulting from the CMI transaction was impaired, resulting in a $4,663,514 impairment charge included in net loss
from discontinued operations.
In accordance with ASC 350, as of December 31,
2021, management concluded that the goodwill resulting from the Cryocann acquisition was not impaired.
Indefinite-Lived Intangible Assets and Intangible
Assets Subject to Amortization
Indefinite-lived intangible assets and intangible
assets subject to amortization are not amortized, but instead are tested annually at December 31 for impairment and upon the occurrence
of certain events or substantive changes in circumstances.
We account for the impairment of indefinite-lived
intangible assets under the provisions of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 350-30-35,
Intangibles – Goodwill and Other – General Intangibles Other Than Goodwill. Following this guidance, the Company compares
the estimated fair value of the indefinite-lived intangible assets to its carrying value. If the carrying value exceeds the fair value,
the Company recognizes impairment equal to that excess.
We account for the impairment of intangible assets
subject to amortization under the provisions of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 360-10-35,
Property, Plant, and Equipment. Following this guidance, the Company compares the estimated fair value of the intangible assets
subject to amortization to its carrying value. If the carrying value exceeds the fair value, the Company recognizes impairment equal to
that excess.
During the year ended December 31, 2020, the Company
concluded that intangible assets resulting from the CMI transaction were impaired, resulting in an impairment charge of $316,218, which
is included in net loss from discontinued operations.
As of December 31, 2021, management concluded
that identifiable intangible assets resulting from the Cryocann transaction were not impaired.
Contingencies
An initial right-of-use (“ROU”) asset
and corresponding liability of $1,411,461 was recognized upon the CMI Transaction. The Company adopted ASU Topic 842 January 1, 2019,
but had no reportable operating leases at that point in time. As of December 31, 2021, our ROU assets and liabilities associated with
CMI were no longer included on the consolidated balance sheets.
CRYOMASS TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
Income Taxes
The Company uses the liability method of accounting
for income taxes as set forth in ASC 740, Income Taxes. Under the liability method, deferred taxes are determined based on the
temporary differences between the financial statement and tax basis of assets and liabilities using tax rates expected to be in effect
during the years in which the basis differences reverse. A valuation allowance is recorded when it is likely that the deferred tax assets
will not be realized. We assess our income tax positions and record tax benefits for all years subject to examination based upon our evaluation
of the facts, circumstances and information available at the reporting date. In accordance with ASC 740-10, for those tax positions where
there is a greater than 50% likelihood that a tax benefit will be sustained, our policy will be to record the largest amount of tax benefit
that is more likely than not to be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information.
For those income tax positions where there is less than 50% likelihood that a tax benefit will be sustained, no tax benefit will be recognized
in the financial statements.
Fair Value Measurements
Certain assets and liabilities of the Company
are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer
a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between
market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs
and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed
in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered
unobservable:
|
● |
Level 1 — Quoted prices in active markets for identical assets or liabilities. |
|
|
|
|
● |
Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. |
|
|
|
|
● |
Level 3 — Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. |
The carrying values reported in the consolidated
balance sheets for cash, prepaid expenses, inventories, accounts payable, notes payable, and taxes payable approximate fair values because
of the immediate or short-term maturities of these financial instruments. There were no other assets or liabilities that require fair
value to be recalculated on a recurring basis.
The fair value of beneficial conversion features
associated with convertible notes and the fair value of warrants are calculated utilizing level 2 inputs.
When multiple instruments are issued in a single
transaction, the total proceeds from the transaction should be allocated among the individual freestanding instruments identified. In
this case, there were warrants issued in conjunction with convertible notes of $4.9 million and $250K and the sale of common stock through
subscription agreements for $679K and $10.3 million. The allocation occurs after identifying (1) all the freestanding instruments and
(2) the subsequent measurement basis for those instruments. The subsequent measurement basis helps inform how the proceeds should be allocated.
After the proceeds are allocated to the freestanding instruments, those instruments should be further evaluated for embedded features
that may need to be bifurcated or separated.
If debt or stock is issued with detachable warrants,
the guidance in ASC 470-20-25-2 (applied by analogy to stock) requires that the proceeds be allocated to the two instruments based on
their relative fair values. This method is generally appropriate if debt or stock is issued with any other freestanding instrument that
is classified in equity (such as a detachable forward contract) or as a liability but not subject to subsequent fair value accounting.
Given that the convertible notes and common stock
that were issued with warrants are both not subject to subsequent fair value accounting treatment, Management determined the relative
fair value method shall be used for allocating the proceeds of the transaction. Under the relative fair value method, the instrument being
analyzed is allocated a portion of the proceeds based on its fair value to the sum of the fair value of all the instruments covered int
the allocation.
Management additionally evaluated the facts and
circumstances to determine whether the principal balance of the Notes ($4.9 million and $250K) approximated their fair value. The Notes
were issued entirely to unrelated third parties which were deemed to be arm’s length transactions. In addition, the comparable interest
rates for loans of similar companies as of the date of the Note issuances range from 10-15% given the liquidity concerns of the Company.
The term of the Notes issued range from 8-15 months, which would support the conclusion that the principal balance approximates their
fair value given the short-term maturities of each Note. Finally, the Warrants issued in connection with the Notes were included akin
to a “sweetener” in the offering as opposed to compensation for adjusting the interest rate or other key terms within the
Convertible Term Loan Agreements. As such, the Company concluded that the principal balance of the Notes approximated their fair value.
The Warrants were initially measured at fair value
and subsequent fair value measurement is not required as long as the instrument continues to be classified in equity. The proceeds from
each transaction were allocated between the Notes and Warrants as well as common stock and Warrants based on the relative fair value method.
Warrants issued in connection with cash provided
for common shares, and not convertible notes, during the fourth quarter of 2021 also followed the same fair value assessment and treatment
as noted above.
CRYOMASS TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
Net Loss per Share
The Company follows ASC 260, Earnings
Per Share, which requires presentation of basic and diluted earnings per share (“EPS”) on the face of the income statement
for all entities with complex capital structures. Net earnings or loss per share is computed by dividing net income or loss by the weighted-average
number of common shares outstanding during the period, excluding shares subject to redemption or forfeiture. The Company presents basic
and diluted net earnings or loss per share. Diluted net earnings or loss per share reflect the actual weighted average of common shares
issued and outstanding during the period, adjusted for potentially dilutive securities outstanding. Potentially dilutive securities are
excluded from the computation of the diluted net loss per share if their inclusion would be anti-dilutive. There were 2,200,003 unvested
RSU’s considered potentially dilutive securities outstanding as of December 31, 2021 and 2,453,172 unvested RSU’s considered
potentially dilutive securities outstanding as of December 31, 2020. Diluted net loss per share is the same as basic net loss per share
for each period.
Assets and Liabilities of Discontinued Operations
Held for Sale
Assets and liabilities are classified as held
for sale when all of the following criteria for a plan of sale have been met: (1) management, having the authority to approve the action,
commits to a plan to sell the assets; (2) the assets are available for immediate sale, in their present condition, subject only to terms
that are usual and customary for sales of such assets; (3) an active program to locate a buyer and other actions required to complete
the plan to sell the assets have been initiated; (4) the sale of the assets is probable and is expected to be completed within one year;
(5) the assets are being actively marketed for a price that is reasonable in relation to their current fair value; and (6) actions required
to complete the plan indicate that it is unlikely that significant changes to the plan will be made or the plan will be withdrawn. When
all of these criteria have been met, the assets (and liabilities) are classified as held for sale in the balance sheet. Assets classified
as held for sale are reported at the lower of their carrying value or fair value less costs to sell. Depreciation of assets ceases upon
designation as held for sale.
Recent Accounting Pronouncements
In August 2020, the Financial Accounting Standards
Board (FASB) issued Accounting Standards Update (ASU) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20)
and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40). ASU 2020-06 reduces the number of accounting
models for convertible debt instruments and convertible preferred stock. The accounting model for beneficial conversion features is removed.
The ASU is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption
is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years.
The Company determined that this update will impact its financial statements.
In August 2018, the FASB issued ASU 2018-13, Fair
Value Measurement (ASC 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. ASU 2018-13 removes
certain disclosures, modifies certain disclosures and adds additional disclosures. The ASU is effective for annual periods, including
interim periods within those annual periods, beginning after December 15, 2019. Early adoption is permitted. The Company has evaluated
that this update will not have a material impact on its financial statements and related disclosures.
In January 2017, the FASB issued ASU 2017-04,
Intangibles-Goodwill and Other (ASC 350), which simplifies the test for goodwill impairment. The ASU is effective for annual periods,
including interim periods within those annual periods, beginning after December 15, 2019. Early adoption is permitted. The Company adopted
this new standard on January 1, 2020.
In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic
842) (ASC 842). In July 2018, the FASB issued ASU No. 2018-10, Codification Improvements to Topic 842, Leases (ASU 2018- 10), which provides
narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU No. 2018-11, Leases (Topic 842)-Targeted
Improvements (ASU 2018-11), which addressed implementation issues related to the new lease standard. Under ASC 842, leases are classified
as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The standard
also requires disclosures to help investors and other financial statement users better understand the amount, timing and uncertainty of
cash flows arising from leases. ASU 2016-02 was effective for annual reporting periods beginning after December 15, 2018 and interim periods
within that reporting period. The Company adopted ASC 842 on January 1, 2019 and used the modified retrospective approach with the effective
date as the date of initial application. Prior period results continue to be presented under ASC 840 based on the accounting standards
originally in effect for such periods.
CRYOMASS TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
5. REVENUE RECOGNITION
Disaggregated Revenue
| |
For the Years Ended December 31, | |
| |
2021 | | |
2020 | |
Types of Revenues: | |
| | |
| |
Medical retail | |
$ | - | | |
$ | 11,200 | |
Medical wholesale | |
| - | | |
| 700 | |
Recreational wholesale | |
| - | | |
| 769,555 | |
Total revenues | |
$ | - | | |
$ | 781,455 | |
6. BUSINESS COMBINATIONS
Effective June 23, 2021, the Company acquired
substantially all the assets of Cryocann for $3,500,000 million in cash and 10,000,000 shares of Company common stock, of which $1,000,000
in cash and 10,000,000 shares of Company common stock were paid at closing and a promissory note was issued for $1,252,316 payable by
Company to Cryocann on October 15, 2021, which represents the remaining Purchase Price of $2,500,000 minus the amount owed by Cryocann
under a Loan Agreement dated April 23, 2021 by and between Cryocann and the Company.
The Company concluded that the Cryocann Acquisition
qualified as a business combination under ASC 805. The Company’s allocation of the purchase price was calculated as follows:
Cash | |
$ | 2,247,684 | |
Common stock | |
| 1,804,500 | |
Promissory Note | |
| 1,220,079 | |
Total purchase price | |
$ | 5,272,263 | |
Description | |
Fair Value | | |
Weighted average useful life (in years) | |
Assets acquired: | |
| | |
| |
Intangible assets: | |
| | |
| |
In process research and development | |
| 3,209,000 | | |
| Indefinite | |
Patent | |
| 873,263 | | |
| 10 | |
Goodwill | |
| 1,190,000 | | |
| | |
Total assets acquired | |
$ | 5,272,263 | | |
| | |
CRYOMASS TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
The following table below represents the revenue,
net loss and loss per share effect of the acquired company, as reported in our pro forma basis as if the acquisition occurred on January
1, 2020. These pro forma results are not necessarily indicative of the results that actually would have occurred if the acquisition had
occurred on the first day of the periods presented, nor does the pro forma financial information purport to represent the results of operations
for future periods.
|
|
For the Years Ended
December 31, |
|
|
|
2021 |
|
|
2020 |
|
Net Sales |
|
$ |
7,641,737 |
|
|
$ |
781,455 |
|
Net loss |
|
$ |
(12,417,483 |
) |
|
$ |
(12,134,840 |
) |
Net loss per common share |
|
$ |
(0.08 |
) |
|
$ |
(0.12 |
) |
7. DISCONTINUED OPERATIONS
In June 2020, the Company’s board of directors
adopted a plan to exit the cultivation, manufacturing of infused products and retail distribution businesses through the sale of CMI.
The Company determined that the intended sale represented a strategic shift that will have a major effect on the Company’s operations
and financial results.
The accompanying consolidated balance sheets include
the following carrying amounts of assets and liabilities related to these CMI discontinued operations:
| |
December 31, 2021 | | |
December 31, 2020 | |
Assets | |
| | |
| |
Accounts receivable, net | |
$ | - | | |
$ | 66,043 | |
Prepaid expenses | |
| - | | |
| 7,601 | |
Inventory, net | |
| - | | |
| 791,868 | |
Property and equipment, net | |
| - | | |
| 2,714,771 | |
Goodwill | |
| - | | |
| - | |
Intangible assets, net | |
| - | | |
| 2,481,128 | |
Security deposits | |
| - | | |
| 11,522 | |
Right of use asset, net | |
| - | | |
| 794,907 | |
Total current assets held for sale | |
| - | | |
| 6,867,840 | |
| |
| | | |
| | |
Total assets held for sale | |
$ | - | | |
$ | 6,867,840 | |
| |
| | | |
| | |
Liabilities | |
| | | |
| | |
Accounts payable and accrued expenses | |
| - | | |
| 211,463 | |
Taxes payable | |
| - | | |
| 22,645 | |
Notes payable, related parties | |
| - | | |
| 458,599 | |
Right of use liability | |
| - | | |
| 771,578 | |
Total liabilities held for sale | |
| - | | |
| 1,464,285 | |
Net assets | |
$ | - | | |
$ | 5,403,555 | |
CRYOMASS TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
The consolidated statements of operations include
the following operating results related to these CMI discontinued operations:
| |
Year Ended December 31, | |
| |
2021 | | |
2020 | |
Net sales | |
$ | 5,891,894 | | |
$ | 6,860,282 | |
Cost of goods sold, inclusive of depreciation | |
| 4,132,696 | | |
| 4,901,237 | |
Gross profit | |
| 1,759,198 | | |
| 1,959,045 | |
| |
| | | |
| | |
Operating expenses: | |
| | | |
| | |
Personnel costs | |
| 428,728 | | |
| 402,389 | |
Sales and marketing | |
| 816,683 | | |
| 908,502 | |
General and administrative | |
| 112,934 | | |
| 231,376 | |
Legal and professional fees | |
| 44,092 | | |
| 156,782 | |
Amortization expense | |
| - | | |
| 26,901 | |
Total operating expenses | |
| 1,402,437 | | |
| 1,725,950 | |
Gain from operations | |
| 356,761 | | |
| 233,095 | |
| |
| | | |
| | |
Other income (expenses): | |
| | | |
| | |
Interest expense | |
| (49,803 | ) | |
| (153,592 | ) |
Goodwill impairment | |
| - | | |
| (4,663,514 | ) |
Intangibles impairment | |
| - | | |
| (361,218 | ) |
Other income | |
| - | | |
| - | |
Total other income (expenses) | |
| (49,803 | ) | |
| (5,178,324 | ) |
Loss on disposal of discontinued operations | |
| (3,021,724 | ) | |
| (4,945,229 | ) |
Net gain / (loss) from discontinued operations, before taxes | |
| (2,714,766 | ) | |
| (4,945,229 | ) |
Income taxes | |
| (10,235 | ) | |
| (10,235 | ) |
Net gain / (loss) from discontinued operations | |
$ | (2,725,001 | ) | |
$ | (4,955,464 | ) |
As discussed in Note 2, we disposed of all CMI-related
assets and extinguished any and all related obligations, resulting in a loss on disposal of discontinued operations of $3,021,724.
CRYOMASS TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
8. PROPERTY AND EQUIPMENT, NET
Property and equipment, net consisted of the following.
| |
December 31, 2021 | | |
December 31, 2020 | |
Leasehold improvements | |
$ | - | | |
$ | 2,770,385 | |
Machinery and equipment | |
| 225,000 | | |
| 1,065,885 | |
Furniture and fixtures | |
| - | | |
| 43,331 | |
Construction in progress | |
| - | | |
| 227,995 | |
| |
| 225,000 | | |
| 4,107,596 | |
Less: Accumulated depreciation | |
| - | | |
| (1,392,825 | ) |
| |
$ | 225,000 | | |
$ | 2,714,771 | |
Depreciation expense for the years ended December
31, 2021 and 2020 was $0 and $131,110, respectively. Depreciation expense was recorded in cost of goods sold and general and administrative
expense and is included in discontinued operations.
9. GOODWILL AND INTANGIBLE ASSETS
The carrying value of goodwill was $1,190,000
and $0, as of December 31, 2021 and December 31, 2020, respectively.
The following tables summarize information relating
to the Company’s identifiable intangible assets as of December 31, 2021. The Company had no identifiable intangible assets as of
December 31, 2020.
| |
Estimated Useful Life (Years) | |
Gross Amount | | |
Accumulated Amortization | | |
Carrying Value | |
Amortized | |
| |
| | | |
| | | |
| | |
Patent | |
10 years | |
| 873,263 | | |
| (43,663 | ) | |
| 829,600 | |
Indefinite-lived | |
| |
| | | |
| | | |
| | |
In-process research and development | |
Indefinite | |
| 3,209,000 | | |
| - | | |
| 3,209,000 | |
Total identifiable intangible assets | |
| |
$ | 4,082,263 | | |
$ | (43,663 | ) | |
$ | 4,038,600 | |
Amortization expense, which is included in continuing
operations, was $43,663 and $0 for the years ended December 31, 2021 and 2020, respectively.
CRYOMASS TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
10. LOAN RECIEVABLE
As a result of new agreements entered with CMI
on December 31, 2021, as further detailed in Note 1 above, we received a $3,600,000 promissory note due to us no later than December 31,
2023. In consideration of the loan receivable, we conveyed to CMI, any and all manufacturing, grow equipment, retail-related assets and
other assets Seller owns in the state of Colorado and are currently used by CMI subsidiaries in the course of business, including client
lists and appertaining intellectual property, and no other Buyer or Parent assets, as well as all liabilities related to these assets.
11. DEBT
On July 27, 2020, the Company entered into a subscription
agreement consisting of 1) a convertible note and 2) warrants. The 1) convertible note has a face value of $250,000, matures August 1,
2022, and accrues interest at 8% per annum. The note is convertible into 2,500,000 shares of the Company’s common stock at a conversion
price of $0.10 per share. The beneficial conversion feature is accounted for in accordance with ASC 470-20 Debt with Conversion and
Other Options and the resulting debt discount is amortized over the life of the note. As of December 31, 2021, the net carrying amount
is $177,083, which consists of the $250,000 convertible note and $72,917 unamortized debt discount. As of December 31, 2020, the net carrying
amount is $52,083, which consists of the $250,000 convertible note and $197,917 unamortized debt discount. The warrants are exercisable
to purchase an additional 2,500,000 shares of common stock at $0.25 per share.
On August 26, 2020, the Company entered into a
$600,000 loan agreement, which accrues interest at 84% per annum. On January 25, 2021, the Company refinanced this loan at 93.6%, to obtain
additional funding. The loan was fully repaid on April 27, 2021, with a $412,560 loan balance as of December 31, 2020.
On March 18, 2021, the Company entered into a
$225,000 note payable, which accrued interest at 15% per annum. The note was fully repaid on May 7, 2021.
Between March 29, 2021 and July 6, 2021, the Company
entered into a series of similar subscription agreements with either domestic or non-US accredited investors, respectively (each, a “Initial
Tranche Subscription Agreement (US)” and, respectively, “Initial Tranche Subscription Agreement (non-US)”) pursuant
to which the Company issued and sold to certain accredited investors, in the initial tranche of a non-brokered private placement (the
“Private Placement”), an aggregate 3,000 units (“Units”), each Unit representing (i) one $1,000 principal amount
term note providing for an optional conversion into shares of Company common stock at a price of $0.20 per share (each the “Initial
Convertible Term Note”) and (ii) a common share warrant for the purchase of 5,000 shares of Company common stock at an exercise
price of $0.40 per share (each an “Initial Warrant”), for aggregate net proceeds of $3,000,000. The Initial Convertible Term
Notes and the Initial Warrants mature on March 31, 2022 and March 31, 2023, respectively, and accrued interest at a rate of 12% per annum
payable on a quarterly basis.
CRYOMASS TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
Between May and July 6, 2021, the Company entered
into a series of substantially similar subscription agreements with either domestic or non-US investors (each, a “Subscription Agreement
(US)”, and, respectively, “Subscription Agreement (non-US)”) pursuant to which the Company issued and sold to certain
accredited investors, in the second tranche of the Private Placement, an aggregate 1,900 units (“Units”), each Unit representing
(i) one $1,000 principal amount term note (each a “Convertible Term Note”) providing for an optional conversion into shares
of Company common stock at a price of $0.20 per share and (ii) a common share warrant for the purchase of 5,000 shares of Company common
stock at an exercise price of $0.40 per share (each a “Warrant”), for additional aggregate net proceeds of $1,900,000. The
Convertible Term Notes and Warrants mature on September 30, 2022 and April 30, 2023, respectively, and accrued interest at a rate of 12%
per annum payable on a quarterly basis.
During the year ended December 31, 2021, we recorded
a $1,444,542 debt discount associated on the $4,900,000 of convertible notes, comprised of additional paid in capital for the fair value
of warrants and a beneficial conversion feature of $928,779 and $515,763, respectively. All notes were converted during the year ended
December 31, 2021, and the entire debt discount was amortized into interest expense during the year.
On August 20, 2021, the Company entered into a
$300,000 loan agreement, which accrues interest at 91.23% per annum. Payment is due on a weekly basis up to the maturity date of May 27,
2021. The loan was fully repaid on October 19, 2021.
12. RELATED PARTY TRANSACTIONS
In conjunction with the CMI Transaction, the Company
assumed a note payable in which the note holder, John Knapp (“Knapp”) is a significant shareholder in the Company. In the
second quarter of 2021, the Company issued 2,500,000 shares to pay off the balance of the note. Effective February 25, 2020, Knapp resigned
as a director of Cryomass Technologies, at which time 200,000 Restricted Stock Units were deemed to have vested and were converted into
200,000 common shares. Refer to Note 2 for additional details on the relationship of CMI as a VIE. The outstanding balance of the notes
payable, related party was $0 and $458,599 as of December 31, 2021 and December 31, 2020, respectively.
In conjunction with the Cryocann Acquisition,
the Company received a promissory note from Matt Armstrong, an employee of the Company, for $281,771. This note receivable was issued
as part of an employment agreement with Matt Armstrong, effective June 22, 2021, and was offset against his signing bonus on October 15,
2021. There was no interest associated with the note.
On August 19, 2021, the Company entered into a
loan agreement of $237,590 with its Chief Executive Officer, Christian Noel. The note accrues interest at 14% per annum and was repaid
on October 22, 2021.
On November 15, 2021, issued 250,000 common shares
and warrants, respectively, to Christian Noel in exchange for $50,000.
CRYOMASS TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
13. SHAREHOLDERS’ EQUITY
From June to August 2019, the Company completed
a private placement for the sale of its common stock. The Company issued 14,325,005 shares of common stock for gross proceeds of $7,162,503,
or $0.50 per share, minus equity issuance costs of $72,096.
In July 2019, the Company issued 13,553,233 shares
of common stock in connection with the CMI Transaction (refer to Note 6).
During the year ended December 31, 2019, the Company
issued 790,000 shares of common stock pursuant to advisory agreements. The fair value of $395,000 was included in legal and professional
fees in the consolidated statements of operations.
In February 2020, the Company issued 400,000 shares
of common stock pursuant to accelerated vesting of RSU’s upon the resignation of a former executive.
In February 2020, the Company issued 200,000 shares
of common stock pursuant to accelerated vesting of RSU’s upon the resignation of a former board member.
In March 2020, the Company issued 1,175,549 shares
of common stock to a former executive per a separation agreement.
In June 2020, four shareholders submitted 15,050,000
shares of common stock for cancellation pursuant to prior agreements among certain shareholders. Accordingly, the Company cancelled 15,050,000
shares of common stock.
In July 2020, the Company issued 10,000 shares
of common stock to a former employee per a separation agreement.
In July 2020, one shareholder submitted 300,000
shares of common stock for cancellation pursuant to prior agreements. Accordingly, the Company cancelled 300,000 shares of common stock.
In August 2020, the Company issued 60,000 shares
of common stock in order to raise capital.
In August 2020, the Company issued 757,895 shares
of common stock to former board members per a separation agreement.
From October to December 2020, the Company issued
3,535,665 shares of common stock in order to raise capital.
From January to March 2021, the Company issued
1,491,819 shares of common stock in order to raise capital.
From April to June 2021, the Company issued 10,000,000
shares of common stock related to the CryoCann transaction, 6,903,172 shares of common stock pursuant to employment agreements, 2,500,000
shares of common stock in exchange for the extinguishment of debt, and 633,125 shares of common stock in exchange for services.
From July to September 2021, the Company issued
798,414 shares of common stock in order to raise capital, 633,707 shares of common stock in exchange for services, and 92,127 shares of
common stock for interest payment on a note payable.
From October to December 2021, the Company issued
50,700,000 shares of common stock in order to raise capital, 1,570,501 shares of common stock in exchange for services, and 24,621,119
shares of common stock in exchange for extinguishment of debt.
Restricted Stock Unit Awards
The Company adopted its 2019 Omnibus Stock Incentive
Plan (the “2019 Plan”), which provides for the issuance of stock options, stock grants and RSUs to employees, directors and
consultants. The primary purpose of the 2019 Plan is to enhance the ability to attract, motivate, and retain the services of qualified
employees, officers and directors. Any RSUs granted under the 2019 Plan will be at the discretion of the Compensation Committee of the
Board of Directors. In April 2021 Board of Directors cancelled the 2019 Plan.
CRYOMASS TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
A summary of the Company’s RSU award
activity for the year ended December 31, 2021 is as follows:
| | |
Restricted Stock Units | | |
Weighted Average Grant Date Fair Value | |
Outstanding at December 31, 2020 | | |
| 2,453,175 | | |
$ | 0.45 | |
Granted | | |
| 6,650,000 | | |
| 0.15 | |
Vested | | |
| (6,903,172 | ) | |
| 0.15 | |
Forfeited | | |
| - | | |
| - | |
Outstanding at December 31, 2021 | | |
| 2,200,003 | | |
$ | 0.45 | |
The total fair value of RSUs vested during the
years ending December 31, 2021 and 2020 was $2,851,102 and $309,790, respectively. As of December 31, 2021 and 2020, there was $78,676
and $600,241, respectively, of unrecognized stock-based compensation cost related to non-vested RSU’s, which is expected to be recognized
over the remaining vesting period.
Stock-based compensation expense relating to RSU’s
was $1,685,066 and $734,752 for the years ending December 31, 2021 and 2020, respectively. Stock-based compensation for the year ending
December 31, 2021 consisted of equity awards forfeited, granted and vested to employees, directors and consultants of the Company in the
amount of $1,272,779, $347,275, and $65,012, respectively.
Stock Option Awards
A summary of the Company’s stock option
activity for the year ended December 31, 2021 is as follows:
| |
Stock
Option
Shares | | |
Weighted
Average
Exercise
Price | | |
Weighted
Average
Remaining
Contractual
Term | | |
Aggregate
Intrinsic
Value | |
Outstanding at December 31, 2020 | |
| 3,500,000 | | |
$ | 0.16 | | |
| 8.8 | | |
$ | 581,591 | |
Granted and vested | |
| 5,000,000 | | |
| 0.20 | | |
| 9.5 | | |
| 987,517 | |
Forfeited | |
| - | | |
| - | | |
| - | | |
| - | |
Outstanding at December 31, 2021 | |
| 8,500,000 | | |
$ | 0.18 | | |
| 9.2 | | |
$ | 1,579,108 | |
During the years ended December 31, 2021 and 2020,
the Company issued 5,000,000 and 3,500,000, respectively, of stock options to certain employees, which vested immediately, for a total
fair value of $968,205 and $555,532, respectively. Stock-based compensation expense relating to stock options was $968,205 and $555,532,
respectively.
Expenses for stock-based compensation is included
on the accompanying consolidated statements of operations in general and administrative expense.
During the year ended December 31, 2021, the Company
issued warrants with the option to purchase 73,950,000 common shares at an exercise price of $0.40 per share. Of these warrants, 15,000,000
shares expire on March 31, 2023, 9,500,000 expire on April 30, 2023, 1,000,000 expire on September 17, 2023, 7,750,000 expire on October
15, 2023, 9,510,000 expire on October 26, 2023, 190,000 expire on November 2, 2023, 27,060,000 expire on November 10, 2023, 1,940,000
expire on November 15, 2023, and 750,000 expire on November 17, 2023.
The fair value of these warrants is $1,867,960,
which is reflected in additional paid in capital.
During the year ended December 31, 2020, the Company
issued 2,500,000 and 4,525,898 warrant shares at an excersice price of $0.25 and $0.30, respectively, which expire on August 1, 2022 and
November 22, 2022, respectively.
The fair value of these warrants is $266,383,
which is reflected in additional paid in capital.
CRYOMASS TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
14. INCOME TAXES
Deferred taxes are provided on a liability method
whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards and deferred
tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts
of assets and liabilities and their tax basis. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management,
it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities
are adjusted for the effects of changes in the tax laws and rates on the date of enactment. The Company recognizes interest and penalties
related to unrecognized tax benefits within income tax expense.
The amounts in the following table are included
in net loss from discontinued operations, net of tax. The provision (benefit) for income taxes for the years ended December 31, 2021 and
2020 consists of:
| |
2021 | | |
2020 | |
Current (benefit) provision | |
| | |
| |
Federal | |
$ | - | | |
$ | - | |
State | |
| - | | |
| - | |
Total Current | |
| - | | |
| - | |
| |
| | | |
| | |
Deferred (benefit) provision | |
| | | |
| | |
Federal | |
$ | 3,724 | | |
$ | 3,724 | |
State | |
| 6,511 | | |
| 6,511 | |
Total Deferred | |
$ | 10,235 | | |
$ | 10,235 | |
| |
| | | |
| | |
Total Provision | |
$ | 10,235 | | |
$ | 10,235 | |
The statutory federal income tax rate (21 percent)
for the years ended December 31, 2021 and 2020 is reconciled to the effective income tax rate as follows:
| |
2021 | | |
2020 | |
| |
Tax | | |
Percentage | | |
Tax | | |
Percentage | |
Income Taxes At Statutory Federal Income Tax Rate | |
$ | (2,202,256 | ) | |
| 21.00 | % | |
$ | (2,517,221 | ) | |
| 21.00 | % |
State Taxes, Net Of Federal Income Tax Benefit | |
| 6,511 | | |
| (0.06 | ) | |
| 6,511 | | |
| (0.05 | ) |
Meals & Entertainment | |
| - | | |
| 0.00 | | |
| 261 | | |
| 0.00 | ) |
Penalties and Fines | |
| - | | |
| 0.00 | | |
| - | | |
| 0.00 | |
Return to Provision Adjustment - Permanent Items | |
| - | | |
| 0.00 | | |
| - | | |
| 0.00 | |
Deferred Only Adjustment | |
| - | | |
| 0.00 | | |
| (228,539 | ) | |
| 1.91 | |
Change in Valuation Allowance | |
| 1,838,803 | | |
| (17.53 | ) | |
| 200,791 | | |
| (1.68 | ) |
Section 280E Expense Disallowance | |
| 367,177 | | |
| (3.50 | ) | |
| 2,548,431 | | |
| (21.26 | ) |
Other | |
| - | | |
| 0.00 | | |
| - | | |
| 0.00 | |
Effective tax | |
$ | 10,235 | | |
| (0.10 | )% | |
$ | 10,235 | | |
| (0.09 | )% |
Deferred tax assets and liabilities by type at
December 31, 2021 and 2020 are as follows:
Deferred Tax Assets (Liabilities): | |
2021 | | |
2020 | |
Stock Compensation | |
$ | (7,335 | ) | |
$ | 62,606 | |
Stock Compensation - Options | |
| 259,057 | | |
| - | |
Accrued Salary | |
| 44,384 | | |
| - | |
Trademark/Trade Name | |
| (8,033 | ) | |
| (4,765 | ) |
Developed Manufacturing Process - Extraction | |
| (53,747 | ) | |
| (31,884 | ) |
Customer Relationships | |
| 1,947 | | |
| 1,158 | |
Patent | |
| 3,589 | | |
| - | |
In-Process Research & Development - CryoCann | |
| (26,376 | ) | |
| - | |
Goodwill - CMI | |
| 179,892 | | |
| 168,688 | |
In-Process Research & Development - CMI | |
| 98,135 | | |
| 105,985 | |
Goodwill - CryoCann | |
| 3,490 | | |
| - | |
NOL - Federal Pre-2018 | |
| 43,367 | | |
| 43,367 | |
NOL - Federal Post-2017 | |
| 2,097,542 | | |
| 377,529 | |
NOL - State | |
| 608,703 | | |
| 294,183 | |
Deferred Tax Assets (Liabilities) | |
$ | 3,244,615 | | |
$ | 1,016,867 | |
| |
| | | |
| | |
Valuation Allowance | |
| (3,269,776 | ) | |
| (1,031,792 | ) |
| |
| | | |
| | |
Net Deferred Tax Assets (Liabilities) | |
$ | (25,160 | ) | |
$ | (14,926 | ) |
CRYOMASS TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
At December 31, 2021 and 2020, the Company had
federal net operating loss carryforwards of approximately $10,194,806 and $2,004,266 that may be offset against future taxable income
from the years 2022 through 2041. State net operating losses were approximately $16,641,692 and $8,042,840 at December 31, 2021 and 2020.
However, as a result of the 2017 Tax Cuts and Jobs Act (“TCJA”) and the 2020 Coronavirus Aid, Relief, and Economic Security
Act (“CARES Act”), any federal net operating losses generated in years beginning after December 31, 2017 and before January
1, 2022 can be carried forward indefinitely to offset taxable income in future periods. The amount of NOLs with no expiration totaled
$9,988,297 as of December 31, 2021. The deferred tax assets before valuation allowance for the net operating losses were $2,749,613 and
$715,079 as of December 31, 2021 and 2020. Should a change in ownership occur, the NOLs would be subject to the limitations set forth
under IRC Section 382.
Management assesses the available positive and
negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets.
On the basis of this evaluation, as of December 31, 2021, the Company has recorded a full valuation allowance against its net deferred
tax assets. The valuation allowance is estimated to be approximately $3,269,776 and $1,031,792 for the years ended December 31, 2021 and
2020, respectively. However, because deferred tax liabilities related to indefinite lived intangibles cannot be used as a source of income
to recognize deferred tax assets with definite lives, the recorded valuation allowance exceeded the net deferred assets resulting in an
overall net deferred tax liability, as reflected in the table above.
The Company has adopted the provisions of ASC
740 which prescribe the procedures for recognition and measurement of tax positions taken or expected to be taken in income tax returns.
As of December 31, 2021, the Company does not have an accrual relating to uncertain tax positions. It is not anticipated that unrecognized
tax benefits would significantly increase or decrease within 12 months of the reporting date.
15. COMMITMENTS & CONTINGENCIES
Occasionally, the Company may be involved in claims
and legal proceedings arising from the ordinary course of its business. The Company records a provision for a liability when it believes
that it is both probable that a liability has been incurred, and the amount can be reasonably estimated. If these estimates and assumptions
change or prove to be incorrect, it could have a material impact on the Company’s consolidated financial statements. Contingencies
are inherently unpredictable, and the assessments of the value can involve a series of complex judgments about future events and can rely
heavily on estimates and assumptions.
Lease Commitments
The Company accounts for lease transactions in
accordance with Topic 842, Leases (“ASC 842”), which requires an entity to recognize a right-of-use (“ROU”)
asset and a lease liability for virtually all leases. Operating lease ROU assets and liabilities are recognized at commencement date based
on the present value of lease payments over the lease term. ROU assets represent the Company’s right to use an underlying asset
for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease.
There are no other leases that meet the reporting
standards of ASU Topic 842 as the Company does not have any other leases with a term exceeding twelve months. Other lease payments not
accounted for under ASU Topic 842 total $59,051 and $73,777 for the years ended December 31, 2021 and 2020, respectively.
An ROU asset of $1,411,461 was recognized upon
the CMI Transaction. The present value of the liabilities decreased by $519,671 and $472,154 for the years ended December 31, 2021 and
2020, respectively. This balance is included in the operating section of the statement of cash flows for the years ended December 31,
2021 and 2020. Operating lease cost was approximately $664,686 and $627,132 for the years ended December 31, 2021 and 2020, respectively.
The right of use assets and lease liabilities
assumed from the CMI transaction were disposed of as part of the disposal of our discontinued operations, which is described in further
detail above.
The Company does not have any leases that have
not yet commenced which are significant.
CRYOMASS TECHNOLOGIES INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
Legal Proceedings
We know of no material, existing or pending legal
proceedings against us, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings
in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material
interest adverse to our company.
16. SUBSEQUENT EVENTS
On January 10, 2022, the Company’s shareholders
approved a new stock incentive plan (the “2022 Stock Incentive Plan”). The purpose of the 2022 Stock Incentive Plan is to
advance the interests of the Company and its stockholders by enabling the Company and its subsidiaries to attract and retain qualified
individuals to perform services, to provide incentive compensation for such individuals in a form that is linked to the growth and profitability
of the Company and increases in stockholder value, and to provide opportunities for equity participation that align the interests of recipients
with those of its stockholders.
Also on January 10, 2022, the Company’s
shareholders approved an amendment to the Company’s Articles of Incorporation to effect a reverse stock split of the issued and
outstanding shares of our Common Stock, par value $0.001 per share, such split to combine a whole number of outstanding shares of our
Common Stock in a range of not less than three (3) shares and not more than ten (10) shares, into one share of Common Stock at any time
prior to March 31, 2022.
On January 12, 2022, the Company issued 735,529
shares of common stock to its three executive officers and 371,058 shares of common stock to two directors at a stock price of $0.27.
On January 17, 2022, Mr. Simon Langelier was elected
to the Company’s Board of Directors. Mr. Langelier holds a Bachelor of Science degree (Honors) in Management Sciences (Operational
Research) from the University of Lancaster, United Kingdom. During his thirty-year career with Philip Morris International, until 2011,
Mr. Langelier served in several senior positions, including President Eastern Europe, Middle East & Africa, President Eastern Asia
and President of Next Generation Products & Adjacent Businesses. He was also Managing Director in numerous countries in Europe and
Columbia. He is currently a director of Imperial Brands PLC. Mr. Langelier is also an Honorary Professorial Fellow at the University of
Lancaster in the United Kingdom and a member of the Dean’s Council of that university’s Management School.
Subsequent to year end, the Company has disbursed
$620,000 in loans to CMI.
F-29
Cryomass Technologies, Inc.
false
303
FY
0001533030
416-7208
0001533030
2021-01-01
2021-12-31
0001533030
2022-03-21
0001533030
2021-06-30
0001533030
2021-12-31
0001533030
2020-12-31
0001533030
2020-01-01
2020-12-31
0001533030
us-gaap:CommonStockMember
2019-12-31
0001533030
us-gaap:AdditionalPaidInCapitalMember
2019-12-31
0001533030
us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember
2019-12-31
0001533030
us-gaap:RetainedEarningsMember
2019-12-31
0001533030
2019-12-31
0001533030
us-gaap:CommonStockMember
2020-01-01
2020-12-31
0001533030
us-gaap:AdditionalPaidInCapitalMember
2020-01-01
2020-12-31
0001533030
us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember
2020-01-01
2020-12-31
0001533030
us-gaap:RetainedEarningsMember
2020-01-01
2020-12-31
0001533030
us-gaap:CommonStockMember
2020-12-31
0001533030
us-gaap:AdditionalPaidInCapitalMember
2020-12-31
0001533030
us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember
2020-12-31
0001533030
us-gaap:RetainedEarningsMember
2020-12-31
0001533030
us-gaap:CommonStockMember
2021-01-01
2021-12-31
0001533030
us-gaap:AdditionalPaidInCapitalMember
2021-01-01
2021-12-31
0001533030
us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember
2021-01-01
2021-12-31
0001533030
us-gaap:RetainedEarningsMember
2021-01-01
2021-12-31
0001533030
us-gaap:CommonStockMember
2021-12-31
0001533030
us-gaap:AdditionalPaidInCapitalMember
2021-12-31
0001533030
us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember
2021-12-31
0001533030
us-gaap:RetainedEarningsMember
2021-12-31
0001533030
crym:GeneralExtractLlcMember
2019-07-01
0001533030
crym:FirstCoumbiaDevcoSASMember
crym:CriticalMassIndustriesMember
2019-07-02
2019-07-15
0001533030
crym:CriticalMassIndustriesMember
2019-07-02
2019-07-15
0001533030
2021-06-01
2021-06-22
0001533030
2021-06-22
0001533030
2021-11-17
0001533030
2021-11-01
2021-11-17
0001533030
srt:ChiefExecutiveOfficerMember
2021-11-01
2021-11-17
0001533030
us-gaap:VariableInterestEntityPrimaryBeneficiaryMember
2021-12-31
0001533030
us-gaap:VariableInterestEntityPrimaryBeneficiaryMember
2020-12-31
0001533030
us-gaap:VariableInterestEntityPrimaryBeneficiaryMember
2021-01-01
2021-12-31
0001533030
us-gaap:VariableInterestEntityPrimaryBeneficiaryMember
2020-01-01
2020-12-31
0001533030
us-gaap:VariableInterestEntityPrimaryBeneficiaryMember
2021-12-31
0001533030
us-gaap:VariableInterestEntityPrimaryBeneficiaryMember
2020-12-31
0001533030
us-gaap:VariableInterestEntityPrimaryBeneficiaryMember
2021-01-01
2021-12-31
0001533030
us-gaap:VariableInterestEntityPrimaryBeneficiaryMember
2020-01-01
2020-12-31
0001533030
crym:CMITransactionsMember
2020-01-01
2020-12-31
0001533030
crym:CMITransactionsMember
2021-12-31
0001533030
srt:MinimumMember
us-gaap:ComputerEquipmentMember
2021-01-01
2021-12-31
0001533030
srt:MaximumMember
us-gaap:ComputerEquipmentMember
2021-01-01
2021-12-31
0001533030
srt:MinimumMember
us-gaap:FurnitureAndFixturesMember
2021-01-01
2021-12-31
0001533030
srt:MaximumMember
us-gaap:FurnitureAndFixturesMember
2021-01-01
2021-12-31
0001533030
srt:MinimumMember
us-gaap:MachineryAndEquipmentMember
2021-01-01
2021-12-31
0001533030
srt:MaximumMember
us-gaap:MachineryAndEquipmentMember
2021-01-01
2021-12-31
0001533030
us-gaap:LeaseholdImprovementsMember
2021-01-01
2021-12-31
0001533030
us-gaap:RetailMember
2021-01-01
2021-12-31
0001533030
us-gaap:RetailMember
2020-01-01
2020-12-31
0001533030
crym:MedicalWholesaleMember
2021-01-01
2021-12-31
0001533030
crym:MedicalWholesaleMember
2020-01-01
2020-12-31
0001533030
crym:RecreationalWholesaleMember
2021-01-01
2021-12-31
0001533030
crym:RecreationalWholesaleMember
2020-01-01
2020-12-31
0001533030
crym:CryocannMember
2021-06-23
2021-06-23
0001533030
2021-10-01
2021-10-15
0001533030
crym:CryocannMember
2021-10-01
2021-10-15
0001533030
crym:CryocannMember
2021-04-23
0001533030
crym:CryocannAcquisitionMember
2021-01-01
2021-12-31
0001533030
crym:CryocannAcquisitionMember
2021-12-31
0001533030
crym:CMITransactionsMember
2021-01-01
2021-12-31
0001533030
crym:CMITransactionsMember
2020-12-31
0001533030
crym:CMITransactionsMember
2021-12-31
0001533030
crym:CMITransactionsMember
2021-01-01
2021-12-31
0001533030
crym:CMITransactionsMember
2020-01-01
2020-12-31
0001533030
us-gaap:LeaseholdImprovementsMember
2021-12-31
0001533030
us-gaap:LeaseholdImprovementsMember
2020-12-31
0001533030
us-gaap:MachineryAndEquipmentMember
2021-12-31
0001533030
us-gaap:MachineryAndEquipmentMember
2020-12-31
0001533030
us-gaap:FurnitureAndFixturesMember
2021-12-31
0001533030
us-gaap:FurnitureAndFixturesMember
2020-12-31
0001533030
us-gaap:ConstructionInProgressMember
2021-12-31
0001533030
us-gaap:ConstructionInProgressMember
2020-12-31
0001533030
us-gaap:PatentsMember
2021-01-01
2021-12-31
0001533030
us-gaap:PatentsMember
2021-12-31
0001533030
crym:InprocessResearchAndDevelopmentMember
2021-01-01
2021-12-31
0001533030
crym:InprocessResearchAndDevelopmentMember
2021-12-31
0001533030
crym:SubscriptionAgreementMember
2020-07-27
0001533030
crym:SubscriptionAgreementMember
2020-07-27
2020-07-27
0001533030
crym:SubscriptionAgreementMember
2021-12-31
0001533030
crym:SubscriptionAgreementMember
2020-12-31
0001533030
crym:LoanAgreementMember
2020-08-26
0001533030
2021-01-25
2021-01-25
0001533030
2021-03-18
0001533030
2021-03-18
2021-03-18
0001533030
us-gaap:PrivatePlacementMember
2021-03-29
2021-07-06
0001533030
crym:SubscriptionAgreementMember
2021-07-06
0001533030
crym:SubscriptionAgreementMember
2021-03-29
2021-07-06
0001533030
us-gaap:PrivatePlacementMember
2021-05-01
2021-07-06
0001533030
us-gaap:ConvertibleDebtMember
2021-07-06
0001533030
2021-05-01
2021-07-06
0001533030
2021-07-06
0001533030
2021-08-01
2021-08-20
0001533030
2021-08-20
0001533030
crym:CMITransactionsMember
2021-06-30
0001533030
us-gaap:RestrictedStockMember
2020-02-25
0001533030
us-gaap:RestrictedStockMember
2020-02-01
2020-02-25
0001533030
2021-08-01
2021-08-19
0001533030
2021-10-01
2021-10-22
0001533030
2021-11-15
0001533030
us-gaap:CommonStockMember
2021-08-31
0001533030
us-gaap:CommonStockMember
2021-06-01
2021-08-31
0001533030
2021-06-01
2021-08-31
0001533030
us-gaap:CommonStockMember
2019-07-01
2019-07-31
0001533030
2019-01-01
2019-12-31
0001533030
crym:ExecutiveMember
2020-02-01
2020-02-29
0001533030
crym:BoardMember
2020-02-01
2020-02-29
0001533030
crym:ExecutiveMember
2020-03-01
2020-03-31
0001533030
crym:ShareholdersMember
2020-06-01
2020-06-30
0001533030
crym:EmployeesMember
2020-07-01
2020-07-31
0001533030
crym:ShareholderOneMember
2020-07-01
2020-07-31
0001533030
crym:RaiseCapitalMember
2020-08-01
2020-08-31
0001533030
crym:BoardMember
2020-08-01
2020-08-31
0001533030
crym:RaiseCapitalMember
2020-10-01
2020-12-31
0001533030
crym:RaiseCapitalMember
2021-01-01
2021-03-31
0001533030
2021-04-01
2021-06-30
0001533030
2021-07-01
2021-09-30
0001533030
2021-10-01
2021-12-31
0001533030
crym:RSUsMember
2021-01-01
2021-12-31
0001533030
crym:RSUsMember
2020-01-01
2020-12-31
0001533030
crym:EmployeesMember
2021-01-01
2021-12-31
0001533030
srt:DirectorMember
2021-01-01
2021-12-31
0001533030
crym:ConsultantsMember
2021-01-01
2021-12-31
0001533030
crym:March312023Member
2021-01-01
2021-12-31
0001533030
crym:April302023Member
2021-01-01
2021-12-31
0001533030
crym:September172023Member
2021-01-01
2021-12-31
0001533030
crym:October152023Member
2021-01-01
2021-12-31
0001533030
crym:October262023Member
2021-01-01
2021-12-31
0001533030
crym:November22023Member
2021-01-01
2021-12-31
0001533030
crym:November102023Member
2021-01-01
2021-12-31
0001533030
crym:November152023Member
2021-01-01
2021-12-31
0001533030
crym:November172023Member
2021-01-01
2021-12-31
0001533030
crym:StockOptionAwardsMember
2021-12-31
0001533030
us-gaap:WarrantMember
2021-12-31
0001533030
us-gaap:WarrantMember
2020-12-31
0001533030
us-gaap:WarrantMember
2021-01-01
2021-12-31
0001533030
us-gaap:WarrantMember
2020-01-01
2020-12-31
0001533030
us-gaap:StockOptionMember
2020-12-31
0001533030
us-gaap:StockOptionMember
2021-01-01
2021-12-31
0001533030
us-gaap:StockOptionMember
2021-12-31
0001533030
crym:IncomeTaxesMember
2021-01-01
2021-12-31
0001533030
crym:IncomeTaxesMember
2020-01-01
2020-12-31
0001533030
us-gaap:SubsequentEventMember
2022-01-10
0001533030
srt:MinimumMember
us-gaap:SubsequentEventMember
2022-01-10
0001533030
srt:MaximumMember
us-gaap:SubsequentEventMember
2022-01-10
0001533030
us-gaap:SubsequentEventMember
2022-03-31
0001533030
crym:ThreeExecutiveOfficersMember
us-gaap:SubsequentEventMember
2022-01-12
0001533030
us-gaap:SubsequentEventMember
2022-01-12
2022-01-12
0001533030
crym:TwoDirectorsMember
us-gaap:SubsequentEventMember
2022-01-12
0001533030
us-gaap:SubsequentEventMember
2022-01-12
0001533030
crym:CMIMember
2021-01-01
2021-12-31
xbrli:shares
iso4217:USD
iso4217:USD
xbrli:shares
xbrli:pure